{
    "clinical_study": {
        "@rank": "26672", 
        "arm_group": [
            {
                "arm_group_label": "600\u338d of DA-3030 Injection", 
                "arm_group_type": "Experimental", 
                "description": "600\u338d of DA-3030 is injected once a day, for 5 continuous days."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo(a salin drip) is injected once a day, for 5 continuous days."
            }
        ], 
        "brief_summary": {
            "textblock": "A multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is\n      designed to evaluate the safety of the DA-3030 injection and to explore the efficacy for\n      Neuropathic pain."
        }, 
        "brief_title": "A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain", 
        "condition": "Diabetic Neuropathy", 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Neuropathies", 
                "Neuralgia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  20\u2264 Age \u2264 70\n\n          -  Diagnosed with Type I or Type II diabetes\n\n          -  HbA1c \u2264 11%\n\n          -  Patients with diabetic neuropathic pain for at least 3 months\n\n          -  Patients corresponding to average pain level of 4 points or mor for 24 hours\n             evaluated with 11-point Likert scale\n\n        Exclusion Criteria:\n\n          -  Neuropathic pain due to other causes\n\n          -  Another stronger pain other than neuropathic pain\n\n          -  Abnormality in blood pressure, weight\n\n          -  Positive reaction in HIV, HBV or HCV\n\n          -  A medical history of mental illness within 6 months\n\n          -  The grade of BDI(Beck Depression Inventory) exceeds 21 points\n\n          -  History of drug/alcohol abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01820715", 
            "org_study_id": "DA3030_DN_I (Version 3.4)"
        }, 
        "intervention": [
            {
                "arm_group_label": "600\u338d of DA-3030 Injection", 
                "intervention_name": "600\u338d of DA-3030 Injection", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "133-791"
                }, 
                "name": "Hanyang University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I Study of the DA-3030 Injection to Evaluate Its Safety and Explore the Efficacy for Diabetic Neuropathic Pain", 
        "overall_official": [
            {
                "affiliation": "Hanyang University", 
                "last_name": "Yoo Heon Ahn, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul St. Mary's Hospital, The Catholic University of Korea", 
                "last_name": "Bong Yeon Cha, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inje University", 
                "last_name": "Kyung Soo Ko, M.D, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonbuk National University Hospital", 
                "last_name": "Tae Sun Park, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hanyang University", 
                "last_name": "Young Soo Park, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Wonju Christian Hospital", 
                "last_name": "Choon Hee Chung, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Pusan National University Hospital", 
                "last_name": "In Joo Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Abnormal score of vital signs measured by following methods: two-sample t-test, Wilcoxon rank sum test, Paired t- test, Wilcoxon signed rank test, McNemar test, Chi-squared test, or/and Fisher's exact test", 
                "safety_issue": "Yes", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Number of Subjects or Incidence with Adverse Events including Adverse Drug Event and Serious Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01820715"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measuring how much the subject feels pain last 24 hours on a scale of one to ten (no pain - most severe pain)", 
                "measure": "Average pain score", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "description": "Measuring how much the subject feels pain last 24 hours on a scale of one to ten (no pain - most severe pain)", 
                "measure": "Most severe pain score", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Measuring how much the subject feels pain last night on a scale of one to ten (no pain - most severe pain)", 
                "measure": "overnight pain score", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}